Cargando…

Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide

Geographic heterogeneity has been observed in fracture risk and efficacy of therapeutic intervention in postmenopausal osteoporosis. The objectives of these analyses were to assess across geographic and ethnic subgroups the heterogeneity of fracture incidence and baseline risk, and consistency of ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClung, Michael R., Williams, Gregory C., Hattersley, Gary, Fitzpatrick, Lorraine A., Wang, Yamei, Miller, Paul D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956009/ https://www.ncbi.nlm.nih.gov/pubmed/29285549 http://dx.doi.org/10.1007/s00223-017-0375-z

Ejemplares similares

Correction to: Geography of Fracture Incidence in Postmenopausal Women with Osteoporosis Treated with Abaloparatide
por: McClung, Michael R., et al.
Publicado: (2018)

Abaloparatide is an Effective Treatment Option for Postmenopausal Osteoporosis: Review of the Number Needed to Treat Compared with Teriparatide
por: Reginster, Jean-Yves, et al.
Publicado: (2018)

Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Erratum for Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study
por: Dhaliwal, Ruban, et al.
Publicado: (2020)

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N.B., et al.
Publicado: (2019)

Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
por: Greenspan, Susan L., et al.
Publicado: (2020)

Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

Correction to: Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
por: Watts, N. B., et al.
Publicado: (2020)

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis
por: Bone, Henry G, et al.
Publicado: (2018)

OR03-1 The Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in Postmenopausal Women with Osteoporosis and Osteoarthritis
por: Lane, Nancy, et al.
Publicado: (2019)

Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis
por: Reginster, J. -Y., et al.
Publicado: (2019)

SAT-519 Effect of Abaloparatide on Bone Mineral Density and Fracture Incidence in a Subset of Younger Postmenopausal Women with Osteoporosis at High Risk for Fracture Representative of Covered Commercial Insurance Enrollees
por: Saag, Kenneth, et al.
Publicado: (2019)

ERRATUM for “Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis”
Publicado: (2020)

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial
por: Cosman, Felicia, et al.
Publicado: (2020)

Profile of Abaloparatide and Its Potential in the Treatment of Postmenopausal Osteoporosis
por: Tella, Sri Harsha, et al.
Publicado: (2017)

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis
por: Dempster, David W, et al.
Publicado: (2021)

Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States
por: Le, Quang A., et al.
Publicado: (2018)

Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability
por: McCloskey, E. V., et al.
Publicado: (2019)

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
por: Miller, Paul D., et al.
Publicado: (2021)

Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual‐Energy X‐Ray Absorptiometry (DXA)
por: Winzenrieth, Renaud, et al.
Publicado: (2022)

Response rates for hip, femoral neck, and lumbar spine bone mineral density in patients treated with abaloparatide followed by alendronate: Results from phase 3 ACTIVExtend
por: Deal, Chad L., et al.
Publicado: (2019)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
por: Hong, Pan, et al.
Publicado: (2023)

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis
por: Masud, Tahir, et al.
Publicado: (2009)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Effects of risedronate on fracture risk in postmenopausal women with osteopenia
por: Siris, E. S., et al.
Publicado: (2007)

Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial
por: Leder, Benjamin Z, et al.
Publicado: (2019)

Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
por: McClung, M. R., et al.
Publicado: (2012)

Role of RANKL inhibition in osteoporosis
por: McClung, Michael
Publicado: (2007)

Emerging Therapies for Osteoporosis
por: McClung, Michael R.
Publicado: (2015)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial
por: Watts, N.B., et al.
Publicado: (2020)

Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States
por: Hiligsmann, Mickaël, et al.
Publicado: (2023)

Abaloparatide Real‐World Patient Experience Study
por: Gold, Deborah T, et al.
Publicado: (2021)

The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial
por: Czerwinski, Edward, et al.
Publicado: (2022)

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
por: Bone, H. G., et al.
Publicado: (2014)

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
por: Bone, H. G., et al.
Publicado: (2015)

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study
por: Cosman, F., et al.
Publicado: (2022)

Progress in osteoporosis and fracture prevention: focus on postmenopausal women
por: Saag, Kenneth G, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_icpfre05gff50cqf13npd809bt